Diabetes, hypertension and dyslipidemia – mortal trio

Česká verzia

Authors: prof. MUDr. Andrej Dukát, CSc.
Authors place of work: II. interná klinika LF UK a UN Bratislava
Published in the journal: Forum Diab 2015; 4(1): 62-66
Category: Topic

Summary

Epidemiological studies indentified three main pathophysiological factors influencing the process of atherothrombosis with its clinical consequencies. Diabetes mellitus, arterial hypertension and dyslipidemia represent comorbidities mostly influencing the current epidemy of cardiovascular diseases and morbidity not only in the developed countries, but as well as in the developing countries. Preventive measures use complex principles influencing their all factors.

Key words:
cardiovascular diseases – diabetes mellitus – comorbidities – cardiovascular prevention – therapy.

Zdroje

1. Rydén L, Grant PJ, Anker SD et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. The Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013; 34(39): 3035–3087.

2. Hansson L, Zanchetti A, Camuthers SG et al. Effects of intensive blood- pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351(9118): 1755–1762.

3. Adler AI, Stratton IM, Neil HA et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36) prospective observational study. BMJ 2000; 321(7258): 412–419.

4. Cushman WC, Evans GW, Byington RP et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362(17): 1575–1585.

5. Bangalore S, Kumar S, Lobach I et al. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials. Circulation 2011; 123(24): 2799–2810.

6. Yusuf S, Teo KK, Pogue J et al. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358(15): 1547–1559.

7. Parving HH, Brenner BM, McMurray JJ et al. Cardiorenal endpoints in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367(23): 2204–2213.

8. Sattar N, Preiss D, Murray HM et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375 (9716): 735–742.

9. Shen S, Shah J, Reyes JJ. Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study. BMJ 2013; 347: f6745. Dostupné z DOI: <http://doi: 10.1136/bmj.f6745>.

10. Weber MA, Bakris GL, Jamerson K et al. Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol 2010; 56(1): 77–85.

11. Kotseva K, Wood D, DeBacker G et al. EUROASPIRE III: a survey on lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009; 16(2): 121–137.

12. Eriksson M, Zethelius B, Eeg-Olofsson K et al. Blood lipids in 75 048 type 2 patients: a population-based survey from the Swedish National diabetes register. Eur J Cardiovasc Prev Rehabil 2011; 18(1): 97–105.

13. Chapman MJ, Ginsberg HN, Amarenco P et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011; 32(11): 1345–1361.

14. Miller M, Stone NJ, Ballantyne C et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2011; 123(20): 2292–2333.

15. Di Angelantonio E, Sanwar N, Perry P et al. Major lipids, apolipo-proteins and risk of vascular disease. JAMA 2009; 302(18): 1993–2000.

16. Mills EJ, O´Regan C, Eyawo O et al. Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of > 40 000 patients. Eur Heart J 2011; 32(11): 1409–1415.

17. Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cho-lesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366(9493): 1267–1278.

18. Taskinen MR, Barter PJ, Enholm C et al. Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes. Diabetologia 2010; 53(9): 1846–1855.

19. Ginsberg HN, Elam MB, Lovato LC et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362(17): 1563–1574.

20. Dukát A, Fábryová Ľ. Možné prístupy na zníženie reziduálneho kardiovaskulárneho rizika u pacientov s diabetes mellitus 2.typu. Kardiológia 2010; 19(6): 474–478.

21. Eckel RH, Jakicic JM, Ard JD et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines . Circulation. 2014; 129(25 Suppl 2): S76-S99. Dostupné z WWW: <http://circ.ahajournals.org/content/early/2013/11/11/01.cir.0000437740.48606.d1>.

22. Kearney PM, Blackwell L, Collins R et al. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371(9607): 117–125.

23. Cannon CP, Steinberg BA, Murphy SA et al. Meta-analysis of car-diovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006; 48(3):438–445.

24. Turbull F, Neal B, Chalmers J et al. Effects of different blood pres-sure-lowering regiments on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165(12): 1410–1419.

25. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011; 217(Suppl 1): S1-S44.

26. Cannon CP. IMPROVE-IT Trial. A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. American Heart Association 2014 Scientific Session, Chicago AHA.

27. Baigent C, Landrey MU, Reith C et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377(9784): 2181–2192.

28. Breza J, Žilinská Z, Bujdák P et al. Urologické komplikácie po transplantácii obličky. Urol Listy 2009; 7(1): 38–48.

29. Bruckert E, Labreuche J, Deplanque D et al. Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis. J Cardiovasc Pharmacol 2011; 57(2): 267–272.

30. Jun M, Foote C, Neal B et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010; 375(9729): 1875–1884.

31. Roth EM, Taskinen MR, Ginsberg HN et al.: Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24 week, double-blind, randomized Phase 3 trial. Int J Cardiol 2014: 46:1–7.

32. Raal F, Dufour R, Turner T et al. The Addition of evolocumab Allows the Majority of Heterozygous Familial Hypercholesterolemic Patients to Achieve Low-density Lipoprotein Cholesterol Goals – Results from the Phase 3 Randomized, Double-blind Placebo-controlled Study. ACC 2014.

33. Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo controlled trial. Lancet 2004; 364(9435): 685–696.

34. Collins R, Armitage J, Parish S et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361(9374): 2005–2016.

35. Sever PS, Poulter NR, Dahlof B et al. Reduction in cardiovascular events with atorvastatin in 2532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm (ASCOT-LLA). Diabetes Care 2005; 28(5): 1151–1157.

36. Galajda P, Mokáň M, Mokáň M. Prediabetické stavy. Súč Klin Pr 2014; 11(1):4–9.